- Proving the quality and stability of fillers … Strengthening the position in the global market –

Humedix, an aesthetic subsidiary of Huons Group, is ramping up efforts to expand the global market reach of it premium hyaluronic acid (HA) fillers.

Humedix Co., Ltd. (CEO Jin-Hwan Kim) announced today that it recently secured the Medical Device License from the Thailand Food and Drug Administration (TFDA) for three of its HA filler products.

The approved products include △Elravie® Premier Soft-L, △Elravie® Premier Deep Line-L, △Revolline® Hara-L(Export name: Charmifil-Mild). 

These products will be distributed in Thailand by MnB Thai, a specialized aesthetic distributor that supplies over 1,500 hospitals and clinics across the country. Humedix expects to rapidly expand its market share in Thailand by leveraging its partnership with MnB Thai and implementing a differentiated sales and marketing strategy.

Elravie® Premier and Revolline® are Korean filler brands developed using Humedix`s high-purity and highly crosslinked HA production technology. These products comply with the European Pharmacopoeia (EP) standards and are formulated with pharmaceutical-grade sterile raw materials registered with Korea’s Drug Master File (DMF). The same ingredients are used in injectables and eye drops, ensuring high safety and purity.

Elravie® Premier features Humedix`s unique Hi-B (High Viscoelasticity-Hybrid) technology, which enhances stability and maintains the inherent viscosity of hyaluronic acid by increasing cross-linking efficiency. Recognized for its quality and safety, Elravie® Premier has obtained the approvals from the European Union (CE), China (NMPA), and Russia (RZN). With the recent approval in Thailand, Elravie®  Premier is now exported to 19 countries, including China and Brazil and continues to see steady sales growth in both domestic and international markets with favorable reviews.

The TFDA approval marks Revolline®`s first international market entry. Revolline®  Hara is a high-viscoelasticity filler that maximizes the advantages of both monophasic and biphasic fillers. It is developed using Humedix`s HiVE (High Viscoelasticity) technology, which enhances crosslinking reaction efficiency while minimizing residual BDDE (a crosslinking agent) through multiple purification processes.

Humedix plans to expand the number of registered countries for Revolline® along with the Elravie® Premier, which is emerging as a global brand. The company aims to establish a diverse lineup of filler products to strengthen its global market presence.

Humedix CEO Kim Jin-hwan stated, “We are delighted to showcase the superior quality and advanced technology of Humedix’s products on the global stage through the TFDA approval of our three HA fillers. Moving forward, we will continue to focus on expanding our influence in overseas markets”.